Tier 2 — strong
A randomized, double-blind placebo-controlled trial of oral creatine monohydrate augmentation for enhanced response to a selective serotonin reuptake inhibitor in women with major depressive disorder
Am J Psychiatry
2012
169(9):937-945
Bibliography
- PubMed
- PMID 22864465
- PubMed Central
- PMC4624319
- Funding
- Supported by NARSAD, the Korean Brain Research Center/Korea Research Foundation, U.S. Department of Veterans Affairs, NIDA and NIMH grants reported by the paper.
- Competing interests
- The paper reports research support for In Kyoon Lyoo from several pharmaceutical companies and consultancy/research-support/patent disclosures for Perry F. Renshaw; see the original publication for the complete author disclosures.
Study snapshot
| Design | Randomized double-blind placebo-controlled augmentation trial |
|---|---|
| Model | Human |
| Sample | 52 women enrolled |
| Intervention | Creatine monohydrate 5 g/day plus escitalopram versus placebo plus escitalopram |
| Duration | 8 weeks |
| Endpoints | Hamilton Depression Rating Scale; Treatment response; Brain bioenergetic markers |
What the study showed, in plain terms
Key findings
What this study can and cannot tell us
Citation network
Articles citing this research paper
Biohack Blueprint analyses that reference this study in their evidence base.
- Creatine Brain Benefits: Memory, Cognition, Sleep Loss and What Is Still UncertainCreatine and the brain: evidence for memory, attention, processing speed, older adults and stressed states—plus why recent systematic reviews disagree.Read analysis
- Creatine for Women: Benefits, Safety, Dose and Life-Stage EvidenceCreatine for women across training, menstruation, menopause and brain health: what female-specific studies show, where evidence is promising and where it remains...Read analysis
Editorial review
Reviewed by the Biohack Blueprint research team
Last verified
